These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18088399)

  • 1. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis.
    Hussein K; Ketterling RP; Hulshizer RL; Kuffel DG; Wiktor AE; Hanson CA; Tefferi A; Van Dyke DL
    Eur J Haematol; 2008 Apr; 80(4):318-21. PubMed ID: 18088399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies.
    Hussein K; Ketterling RP; Dewald GW; Van Dyke DL; Mesa R; Hanson CA; Tefferi A
    Leuk Res; 2008 Oct; 32(10):1597-600. PubMed ID: 18241918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
    Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.
    Arora B; Sirhan S; Hoyer JD; Mesa RA; Tefferi A
    Br J Haematol; 2005 Jan; 128(1):42-8. PubMed ID: 15606548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
    Konopleva M; Cheng SC; Cortes JE; Hayes KJ; Pierce SA; Andreeff M; Giles FJ; O'Brien S; Kantarjian HM; Estey EH
    Haematologica; 2003 Jul; 88(7):733-6. PubMed ID: 12857550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Counts in Hematologic Malignancies Predict Low Metaphase Yield for Cytogenetic Analysis.
    Chacko MP; Yuvarani S; Kalaiyarasi JP; Radhakrishnan V; Gowri M; Kamath V
    Am J Clin Pathol; 2022 Sep; 158(3):395-400. PubMed ID: 35666253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical and cytogenetic features of hematologic malignancies associated with acquired trisomy 21].
    Wang H; Ni W; Chen Z; Lou J; Xu H; Yu Y; Qian W; Jin J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):576-8. PubMed ID: 18841576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for leukemic transformation in patients with primary myelofibrosis.
    Huang J; Li CY; Mesa RA; Wu W; Hanson CA; Pardanani A; Tefferi A
    Cancer; 2008 Jun; 112(12):2726-32. PubMed ID: 18404742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia.
    Xubo G; Xingguo L; Xianguo W; Rongzhen X; Xibin X; Lin W; Lei Z; Xiaohong Z; Genbo X; Xiaoying Z
    Eur J Haematol; 2009 Oct; 83(4):292-301. PubMed ID: 19500135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC
    Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jumping translocations in hematological malignancies: a cytogenetic study of five cases.
    Manola KN; Georgakakos VN; Stavropoulou C; Spyridonidis A; Angelopoulou MK; Vlachadami I; Katsigiannis A; Roussou P; Pantelias GE; Sambani C
    Cancer Genet Cytogenet; 2008 Dec; 187(2):85-94. PubMed ID: 19027489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: Hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis.
    Sari I; Altuntas F; Hacioglu S; Kocyigit I; Sevinc A; Sacar S; Deniz K; Alp E; Eser B; Yildiz O; Kaynar L; Unal A; Cetin M
    Am J Hematol; 2008 Apr; 83(4):334-9. PubMed ID: 18069671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of bone marrow and peripheral blood cytologic features in hyperleukocytic acute leukemia].
    Liu YL; Liu HB; Wang WJ; Ma L; Wang XN; Liu HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):562-6. PubMed ID: 23815898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marker chromosomes are a significant mechanism of high-level RUNX1 gene amplification in hematologic malignancies.
    Moosavi SA; Sanchez J; Adeyinka A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):24-8. PubMed ID: 19167608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.
    Tefferi A; Gangat N; Wolanskyj AP; Schwager S; Pardanani A; Lasho TL; Mesa R; McClure RF; Li CY; Hanson CA
    Eur J Haematol; 2008 May; 80(5):386-90. PubMed ID: 18221390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia.
    Weinkauff R; Estey EH; Starostik P; Hayes K; Huh YO; Hirsch-Ginsberg C; Andreeff M; Keating M; Kantarjian HM; Freireich EJ; Albitar M
    Am J Clin Pathol; 1999 Jun; 111(6):733-40. PubMed ID: 10361507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional cytogenetics in myelofibrosis: literature review and discussion.
    Hussein K; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 May; 82(5):329-38. PubMed ID: 19141119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
    Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
    Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal.
    Breccia M; Latagliata R; Cannella L; Carmosino I; De Cuia R; Frustaci A; Stefanizzi C; Santopietro M; Alimena G
    Leuk Res; 2009 Mar; 33(3):391-4. PubMed ID: 18676015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.